Medication Description: Leuprorelin (Leuprorelin)
Synonyms: Lyukrin Depot, Prostap, Lucrin depot, Prostap.
6-D-Leucine-9- (N-ethyl-L-prolinamide) -10-deglycinamide-luteinizing hormone-releasing factor (porcine).
Analogue gonadotropin-releasing factor.
Available in the form of acetate (C 59 H 84 N 16 O 12 · C 2 H 4 O 2 ).
By action close to buserelin (see).
After intramuscular administration, leuprorelin is released from the copolymer within 1 month, while the content of sex hormones increases during the first 7 days, and by the 21-28th day it decreases and remains at this level with the subsequent administration of the drug.
Bioavailability makes 75-98%, T Ѕ - 3 h.
Applied with hormone-dependent prostate cancer, as well as with uterine fibroids and endometriosis.
Available in the form of lyophilized microspheres in vials of 3.75 and 7.5 mg, complete with solvent. The drug is administered intramuscularly or subcutaneously 1 time per month: for prostate cancer - 3.75 or 7.5 mg; with uterine fibroids and endometriosis - 3.75 mg. The course of treatment is not more than 6 months.
Possible side effects: headache, dizziness, sleep disturbance, dyspepsia, swelling of the face and legs, impaired vision and hearing, depression, decreased libido; in men, impotence, gynecomastia, reduction of the testes; in women, vaginitis, acne, hirsutism, decreased bone density.
The drug is contraindicated in hormone-independent prostate cancer.